Fig. 1: Genomic MCL-1 gains in cancer.
From: MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically
a Number of significantly gained and expressed genes located on chromosome arm 1q in the TCGA cohort. The bars pointing to the right demonstrate the number of significant genes identified in up to 1 to 24 cancer types (right bars). The numbers are represented as cumulative counts, which means that genes significant in two cancer types were also counted in for one cancer type. MCL-1 was found to be significantly gained and expressed in 22 cancer types among 140 other genes. b MCL-1 gains (CNA, copy number aberrations) in TCGA LUAD samples. LLG low-level gain, HLG high-level gain. n = 652. c Correlation between MCL-1 CNA and mRNA levels in TCGA LUAD samples. n = 456 (289 gain and 167 no gain, p = 1e−07, W = 17,081). d MCL-1 gains (CNA) in TCGA LUSC samples. n = 652. e Correlation between MCL-1 CNA and mRNA levels in TCGA LUSC samples. n = 441 (164 gain and 277 no gain, p = 1.6e−04, W = 18,066). f, g CNA expressed as frequency in TRACERx LUAD (f, n = 61) and LUSC (g, n = 32) tumours. Shading indicates clonal status. Dashed purple lines represent threshold for frequent gains and losses. h, i Correlation between CNA and mRNA levels of MCL-1 in TRACERx LUAD (h) and LUSC (i) tumour regions. For LUAD, n = 93 (60 gain and 33 no gain, p = 0.017, W = 1256). For LUSC, n = 50 (22 gain and 28 no gain, p = 0.0028, W = 448). Data in (c, e, h, and i) are presented as box plot and were analysed by a one-sided Wilcoxon test. In the box plots, the centre line represents the median value, the limits represent the 25th and 75th percentile, the whiskers represent the minimum and maximum value of the distribution excluding outliers defined by the inter-quartile range (IQR) rule. The points represent the individual experimental values.
